Sarepta Therapeutics (NASDAQ: SRPT) could see some wild trading once it's FDA panel for DMD drug eteplirsen is completed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE